Close

Regeneron (REGN), Teva Pharma (TEVA) Enter Partnership for Fasinumab Development, Commercialization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Regeneron (REGN), Teva Pharma (TEVA) Enter Partnership for Fasinumab Development, Commercialization

Roth Capital Reiterates Regeneron (REGN) at 'Buy' Following New Teva Pharma Ffasinumab Partnership

September 20, 2016 12:22 PM EDT

Roth Capital affirms Regeneron Pharma (Nasdaq: REGN) at Buy with a price target of $520 after the company and Teva Pharma announced a global agreement to develop and commercialize... More